Julia Sundheimer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Julia Sundheimer has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Jürgen Burhenne
Heidelberg University
2 shared publications - Margaux Fresnais
Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
2 shared publications - Rémi Longuespée
Department of Clinical Pharmacology and Pharmacoepidemiology Heidelberg University Hospital Heidelberg Germany
2 shared publications - Siwen Liang
Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
2 shared publications - Walter Emil Haefeli
Heidelberg University
2 shared publications Aniello Federico
Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany
1 shared publication
Latest Publications
- Open Access
- 10 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 12061
Ependymoma group-specific blood-brain barrier differences uncovered by a multi-omics approach
A significant obstacle in treating brain tumors is the limited drug penetration across the blood-brain barrier (BBB), characterized by an interplay of endothelial tight junctions and efflux pumps. Brain tumors can alter BBB characteristics; however, there is limited understanding in ependymoma (EPN), the third most common pediatric brain tumor. To this end, we characterized EPN tumor ( n = 364) and healthy brain tissues ( n = 225) at RNA level and identified a distinct EPN group-specific BBB transcriptional pattern. Analyses of public datasets from Aubin and Gojo as well as a validation single-cell dataset ( n = 8) could further specify a novel BBB signature expressed in an endothelial subpopulation. Clinically relevant drugs ( n = 3) that were effective against EPN in vitro were further evaluated for BBB penetration in our subtype-specific patient-derived xenograft (PDX) models. Idasanutlin showed overall low brain-to-plasma ratios, while the P-glycoprotein (PGP) substrates temsirolimus and etoposide accumulated slightly more in zinc finger translocation associated (ZFTA)-fusion positive EPN than in PFA tumors and adjacent brain. These differences align with modestly lower PGP levels in ZFTA PDX, although expression does not necessarily reflect transporter activity and was not consistently observed in patient tumors. Despite these differences, all tested drugs remained below their effective in vitro levels. In summary, multi-omics analyses of BBB characteristics improve the understanding of drug penetrance and may potentially guide treatment choices in the context of molecular EPN groups within upcoming clinical trials.
- 10 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 12061
Open AccessEpendymoma group-specific blood-brain barrier differences uncovered by a multi-omics approach
A significant obstacle in treating brain tumors is the limited drug penetration across the blood-brain barrier (BBB), characterized by an interplay of endothelial tight junctions and efflux pumps. Brain tumors can alter BBB characteristics; however, there is limited understanding in ependymoma (EPN), the third most common pediatric brain tumor. To this end, we characterized EPN tumor ( n = 364) and healthy brain tissues ( n = 225) at RNA level and identified a distinct EPN group-specific BBB transcriptional pattern. Analyses of public datasets from Aubin and Gojo as well as a validation single-cell dataset ( n = 8) could further specify a novel BBB signature expressed in an endothelial subpopulation. Clinically relevant drugs ( n = 3) that were effective against EPN in vitro were further evaluated for BBB penetration in our subtype-specific patient-derived xenograft (PDX) models. Idasanutlin showed overall low brain-to-plasma ratios, while the P-glycoprotein (PGP) substrates temsirolimus and etoposide accumulated slightly more in zinc finger translocation associated (ZFTA)-fusion positive EPN than in PFA tumors and adjacent brain. These differences align with modestly lower PGP levels in ZFTA PDX, although expression does not necessarily reflect transporter activity and was not consistently observed in patient tumors. Despite these differences, all tested drugs remained below their effective in vitro levels. In summary, multi-omics analyses of BBB characteristics improve the understanding of drug penetrance and may potentially guide treatment choices in the context of molecular EPN groups within upcoming clinical trials.
- Open Access
- 9 May 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (10) , 8469
Desorption Kinetics Evaluation for the Development of Validated Desorption Electrospray Ionization-Mass Spectrometric Assays for Drug Quantification in Tissue Sections
The development of desorption/ionization (DI) mass spectrometric (MS) assays for drug quantification in tissue sections and their validation according to regulatory guidelines would enable their universalization for applications in (clinical) pharmacology. Recently, new enhancements in desorption electrospray ionization (DESI) have highlighted the reliability of this ion source for the development of targeted quantification methods that meet requirements for method validation. However, it is necessary to consider subtle parameters leading to the success of such method developments, such as the morphology of desorption spots, the analytical time, and sample surface, to cite but a few. Here, we provide additional experimental data highlighting an additional important parameter, based on the unique advantage of DESI-MS on continuous extraction during analysis. We demonstrate that considering desorption kinetics during DESI analyses would largely help (i) reducing analytical time during profiling analyses, (ii) verifying solvent-based drug extraction using the selected sample preparation method for profiling and imaging modes, and (iii) predicting the feasibility of imaging assays using samples in a given expected concentration range of the targeted drug. These observations will likely serve as precious guidance for the development of validated DESI-profiling and imaging methods in the future.
- 9 May 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (10) , 8469
Open AccessDesorption Kinetics Evaluation for the Development of Validated Desorption Electrospray Ionization-Mass Spectrometric Assays for Drug Quantification in Tissue Sections
The development of desorption/ionization (DI) mass spectrometric (MS) assays for drug quantification in tissue sections and their validation according to regulatory guidelines would enable their universalization for applications in (clinical) pharmacology. Recently, new enhancements in desorption electrospray ionization (DESI) have highlighted the reliability of this ion source for the development of targeted quantification methods that meet requirements for method validation. However, it is necessary to consider subtle parameters leading to the success of such method developments, such as the morphology of desorption spots, the analytical time, and sample surface, to cite but a few. Here, we provide additional experimental data highlighting an additional important parameter, based on the unique advantage of DESI-MS on continuous extraction during analysis. We demonstrate that considering desorption kinetics during DESI analyses would largely help (i) reducing analytical time during profiling analyses, (ii) verifying solvent-based drug extraction using the selected sample preparation method for profiling and imaging modes, and (iii) predicting the feasibility of imaging assays using samples in a given expected concentration range of the targeted drug. These observations will likely serve as precious guidance for the development of validated DESI-profiling and imaging methods in the future.
- Open Access
- 12 August 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (16) , 9011
Microglia Impairs Proliferation and Induces Senescence In-Vitro in NGF Releasing Cells Used in Encapsulated Cell Biodelivery for Alzheimer’s Disease Therapy
There is no cure yet available for Alzheimer’s disease (AD). We recently optimized encapsulated cell biodelivery (ECB) devices releasing human mature nerve growth factor (hmNGF), termed ECB-NGF, to the basal forebrain of AD patients. The ECB-NGF delivery resulted in increased CSF cholinergic markers, improved glucose metabolism, and positive effects on cognition in AD patients. However, some ECB-NGF implants showed altered hmNGF release post-explantation. To optimize the ECB-NGF platform for future therapeutic purposes, we initiated in-vitro optimization studies by exposing ECB-NGF devices to physiological factors present within the AD brain. We report here that microglia cells can impair hmNGF release from ECB-NGF devices in-vitro, which can be reversed by transferring the devices to fresh culture medium. Further, we exposed the hmNGF secreting human ARPE-19 cell line (NGC0211) to microglia (HMC3) conditioned medium (MCM; untreated or treated with IL-1β/IFNγ/Aβ40/Aβ42), and evaluated biochemical stress markers (ROS, GSH, ΔΨm, and Alamar Blue assay), cell death indicators (Annexin-V/PI), cell proliferation (CFSE retention and Ki67) and senescence markers (SA-β-gal) in NGC0211 cells. MCMs from activated microglia reduced cell proliferation and induced cell senescence in NGC0211 cells, which otherwise resist biochemical alterations and cell death. These data indicate a critical but reversible impact of activated microglia on NGC0211 cells.
- 12 August 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (16) , 9011
Open AccessMicroglia Impairs Proliferation and Induces Senescence In-Vitro in NGF Releasing Cells Used in Encapsulated Cell Biodelivery for Alzheimer’s Disease Therapy
There is no cure yet available for Alzheimer’s disease (AD). We recently optimized encapsulated cell biodelivery (ECB) devices releasing human mature nerve growth factor (hmNGF), termed ECB-NGF, to the basal forebrain of AD patients. The ECB-NGF delivery resulted in increased CSF cholinergic markers, improved glucose metabolism, and positive effects on cognition in AD patients. However, some ECB-NGF implants showed altered hmNGF release post-explantation. To optimize the ECB-NGF platform for future therapeutic purposes, we initiated in-vitro optimization studies by exposing ECB-NGF devices to physiological factors present within the AD brain. We report here that microglia cells can impair hmNGF release from ECB-NGF devices in-vitro, which can be reversed by transferring the devices to fresh culture medium. Further, we exposed the hmNGF secreting human ARPE-19 cell line (NGC0211) to microglia (HMC3) conditioned medium (MCM; untreated or treated with IL-1β/IFNγ/Aβ40/Aβ42), and evaluated biochemical stress markers (ROS, GSH, ΔΨm, and Alamar Blue assay), cell death indicators (Annexin-V/PI), cell proliferation (CFSE retention and Ki67) and senescence markers (SA-β-gal) in NGC0211 cells. MCMs from activated microglia reduced cell proliferation and induced cell senescence in NGC0211 cells, which otherwise resist biochemical alterations and cell death. These data indicate a critical but reversible impact of activated microglia on NGC0211 cells.
- Open Access
- 1 June 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (6) , 694
Analytical Performance Evaluation of New DESI Enhancements for Targeted Drug Quantification in Tissue Sections
Desorption/ionization (DI)-mass spectrometric (MS) methods offer considerable advantages of rapidity and low-sample input for the analysis of solid biological matrices such as tissue sections. The concept of desorption electrospray ionization (DESI) offers the possibility to ionize compounds from solid surfaces at atmospheric pressure, without the addition of organic compounds to initiate desorption. However, severe drawbacks from former DESI hardware stability made the development of assays for drug quantification difficult. In the present study, the potential of new prototype source setups (High Performance DESI Sprayer and Heated Transfer Line) for the development of drug quantification assays in tissue sections was evaluated. It was demonstrated that following dedicated optimization, new DESI XS enhancements present promising options regarding targeted quantitative analyses. As a model compound for these developments, ulixertinib, an inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2 was used.
- 1 June 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (6) , 694
Open AccessAnalytical Performance Evaluation of New DESI Enhancements for Targeted Drug Quantification in Tissue Sections
Desorption/ionization (DI)-mass spectrometric (MS) methods offer considerable advantages of rapidity and low-sample input for the analysis of solid biological matrices such as tissue sections. The concept of desorption electrospray ionization (DESI) offers the possibility to ionize compounds from solid surfaces at atmospheric pressure, without the addition of organic compounds to initiate desorption. However, severe drawbacks from former DESI hardware stability made the development of assays for drug quantification difficult. In the present study, the potential of new prototype source setups (High Performance DESI Sprayer and Heated Transfer Line) for the development of drug quantification assays in tissue sections was evaluated. It was demonstrated that following dedicated optimization, new DESI XS enhancements present promising options regarding targeted quantitative analyses. As a model compound for these developments, ulixertinib, an inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2 was used.